Cargando…

Tocilizumab: The Key to Stop Coronavirus Disease 2019 (COVID-19)-Induced Cytokine Release Syndrome (CRS)?

The COVID-19 disease is an unprecedented international public health emergency and considerably impacts the global economy and health service system. While awaiting the development of an effective vaccine, searching for the therapy for severe or critical COVID-19 patients is essential for reducing t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Danfei, Zhang, Tongyue, Wang, Yijun, Xia, Limin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7649275/ https://www.ncbi.nlm.nih.gov/pubmed/33195318 http://dx.doi.org/10.3389/fmed.2020.571597

Ejemplares similares

FGF/FGFR Signaling in Hepatocellular Carcinoma: From Carcinogenesis to Recent Therapeutic Intervention
por: Wang, Yijun, et al.
Publicado: (2021)

The Centrality of Obesity in the Course of Severe COVID-19
por: Liu, Danfei, et al.
Publicado: (2021)

Therapeutic Effect of Tocilizumab on Inhibiting Cytokine Release Syndrome in Severe Coronavirus Disease 2019 Patients
por: Xu, Lengnan, et al.
Publicado: (2022)

Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?
por: Liu, Bingwen, et al.
Publicado: (2020)

Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes
por: Price, Christina C., et al.
Publicado: (2020)

The E-Twenty-Six Family in Hepatocellular Carcinoma: Moving into the Spotlight
por: Zhang, Tongyue, et al.
Publicado: (2021)

P911: EVALUATION OF PROPHYLACTIC TOCILIZUMAB (TOCI) FOR THE REDUCTION OF CYTOKINE RELEASE SYNDROME (CRS) TO INFORM THE MANAGEMENT OF PATIENTS (PTS) TREATED WITH TECLISTAMAB IN MAJESTEC-1
por: van de Donk, Niels W.C.J., et al.
Publicado: (2023)

Cytokine Release Syndrome (CRS) and Nicotine in COVID-19 Patients: Trying to Calm the Storm
por: Gonzalez-Rubio, Jesus, et al.
Publicado: (2020)

Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies
por: Leclercq-Cohen, Gabrielle, et al.
Publicado: (2023)

Need for aligning the definition and reporting of cytokine release syndrome (CRS) in immuno-oncology clinical trials
por: Stewart, Mark D., et al.
Publicado: (2022)

The deregulated immune reaction and cytokines release storm (CRS) in COVID-19 disease
por: Pasrija, Ritu, et al.
Publicado: (2021)

The roles of nausea and vomiting in COVID-19: did we miss something?
por: Zhang, Tongyue, et al.
Publicado: (2021)

Interleukin-6 Antagonist Tocilizumab to Treat Critically Ill Coronavirus Disease 2019 Patients With Cytokine Release Syndrome: A Case Series
por: Yang, Stephen Su, et al.
Publicado: (2021)

Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies
por: Kauer, Joseph, et al.
Publicado: (2020)

The effect of tocilizumab on cytokine release syndrome in COVID-19 patients
por: de Cáceres, Carmen, et al.
Publicado: (2020)

Utilizing tocilizumab for the treatment of cytokine release syndrome in COVID-19
por: Hassoun, Ali, et al.
Publicado: (2020)

Cytokine Release Syndrome (CRS) in Severe COVID-19 Patients: Two Controversial and Interesting Case Reports and Literature Review
por: Lazovic, Biljana, et al.
Publicado: (2023)

Effectiveness of Tocilizumab in a COVID-19 Patient with Cytokine Release Syndrome
por: Uslu, Sadettin
Publicado: (2020)

Tocilizumab in Severe COVID-19 Pneumonia and Concomitant Cytokine Release Syndrome
por: van Kraaij, Tom DA, et al.
Publicado: (2020)

Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality
por: Zhang, Chi, et al.
Publicado: (2020)

Macrophage, the potential key mediator in CAR-T related CRS
por: Hao, Zhaonian, et al.
Publicado: (2020)

Spotlight on Tocilizumab in the Treatment of CAR-T-Cell-Induced Cytokine Release Syndrome: Clinical Evidence to Date
por: Si, Stephanie, et al.
Publicado: (2020)

Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome: A Cautionary Case Report
por: Radbel, Jared, et al.
Publicado: (2020)

ONECUT2 facilitates hepatocellular carcinoma metastasis by transcriptionally upregulating FGF2 and ACLY
por: Liu, Danfei, et al.
Publicado: (2021)

Correction to: ONECUT2 facilitates hepatocellular carcinoma metastasis by transcriptionally upregulating FGF2 and ACLY
por: Liu, Danfei, et al.
Publicado: (2021)

Tocilizumab Use in COVID-19 Cytokine-release Syndrome: Retrospective Study of Two Centers
por: Nasa, Prashant, et al.
Publicado: (2020)

Is There Still a Place for Tocilizumab in Coronavirus Disease 2019?
por: Klopfenstein, Timothée, et al.
Publicado: (2021)

Homeobox B5 promotes metastasis and poor prognosis in Hepatocellular Carcinoma, via FGFR4 and CXCL1 upregulation
por: He, Qin, et al.
Publicado: (2021)

P1414: CRP IS A CONVENIENT PREDICTIVE MARKER OF THE ANTIPYRETIC EFFECT OF TOCILIZUMAB ON CRS DURING CAR-T CELL THERAPY
por: Yokoyama, Shota, et al.
Publicado: (2023)

Late Post-Coronavirus Disease 2019 Inflammatory Syndrome: A Case Experience with Tocilizumab
por: Tabarsi, Payam, et al.
Publicado: (2021)

Tocilizumab in a child with acute lymphoblastic leukaemia and COVID-19-related cytokine release syndrome()
por: Velasco Puyó, Pablo, et al.
Publicado: (2020)

Questioning Tocilizumab Use in Hospitalized Patients With Coronavirus Disease 2019
por: Mombrun, Martin, et al.
Publicado: (2021)

Cytokine Release Syndrome Following Blinatumomab Therapy
por: Ojemolon, Pius E, et al.
Publicado: (2022)

Investigation of CRS-associated cytokines in CAR-T therapy with meta-GNN and pathway crosstalk
por: Wei, Zhenyu, et al.
Publicado: (2022)

ACE/ACE2 Ratio: A Key Also in 2019 Coronavirus Disease (Covid-19)?
por: Pagliaro, Pasquale, et al.
Publicado: (2020)

Tocilizumab and Cytokine Release Syndrome in COVID-19 Pneumonia: Experience From a Single Center in Pakistan
por: Hassan, Muhammad, et al.
Publicado: (2021)

HGF-mediated elevation of ETV1 facilitates hepatocellular carcinoma metastasis through upregulating PTK2 and c-MET
por: Zhang, Tongyue, et al.
Publicado: (2022)

Evaluation of infliximab/tocilizumab versus tocilizumab among COVID-19 patients with cytokine storm syndrome
por: Sarhan, Neven Mohamed, et al.
Publicado: (2023)

Case report: use of lenzilumab and tocilizumab for the treatment of coronavirus disease 2019
por: Melody, Megan, et al.
Publicado: (2020)

Tocilizumab for coronavirus disease 2019 in pregnancy and lactation: a narrative review
por: Jorgensen, Sarah C.J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vlrtm2laogqdcaai81gksddpfv